Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

Back

ESC Professional Premium Access

Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

Session: Hypertension - Pharmacotherapy

Topic: Pharmacotherapy

Speaker: Doctor M. Freeman (Boston, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Mason Freeman

CinCor Pharma, Boston (United States of America)

0 follower

7 more presentations in this session

Intensive reduction of high normal blood pressures: PRINT-TAHA9 randomized clinical trial

Speaker: Associate Professor A. Attar (Shiraz, IR)

Access

Abstract

Slides

Differentiated approach to the treatment of uncomplicated hypertensive crisis

Speaker: Doctor M. Sadulloeva (Tashkent, UZ)

Access

Abstract

Slides

Blockade of the renin-angiotensin system as a therapeutic target of NAFLD: results of an experimental model of hypercholesterolemia

Speaker: Professor D. Bertolim Precoma (Campina Grande do Sul, BR)

Access

Abstract

Slides

Hydrochlorothiazide does not lead to phototoxic reactions and DNA damage in healthy volunteers the HCTox study

Speaker: Doctor F. Goetzinger (Homburg, DE)

Access

Abstract

Slides

Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

Speaker: Doctor A. Liontos (Ioannina, GR)

Access

Abstract

Slides

Access the full session

Hypertension - Pharmacotherapy

Speakers: Doctor M. Freeman, Associate Professor A. Attar, Doctor M. Sadulloeva, Professor D. Bertolim Precoma, Doctor F. Goetzinger...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources